U.S. Peptide Groups Form GMP Alliance

Lifecore and PolyPeptide link domestic API and fill-finish capacity as demand for peptide drugs grows

24 Feb 2026

A new US partnership between Lifecore Biomedical and PolyPeptide aims to streamline the manufacturing of peptide medicines, as demand rises across metabolic, oncology and rare disease treatments.

The companies have agreed to combine their capabilities to offer an integrated, US-based good manufacturing practice, or GMP, solution. The arrangement links large-scale production of peptide active pharmaceutical ingredients, known as APIs, with sterile formulation and fill-finish services, areas that are often handled by separate contractors.

Peptide therapies have attracted growing investment in recent years, particularly in metabolic disease. As more candidates move from clinical development towards commercial supply, drug developers are seeking manufacturing models that reduce operational risk and simplify oversight.

Under traditional contract development and manufacturing organisation structures, sponsors may rely on multiple vendors across synthesis, formulation and packaging. Such fragmentation can increase the complexity of technology transfers and quality alignment, and add to project management demands.

PolyPeptide brings experience in peptide API manufacturing across global sites, while Lifecore specialises in sterile injectable development and fill-finish operations. The companies said the collaboration is intended to reduce handovers between suppliers and provide a more continuous path from early development through to commercial production.

The focus on US-based capacity also reflects broader industry concerns about supply chain resilience. Policymakers and pharmaceutical groups have in recent years highlighted vulnerabilities in cross-border supply chains, particularly for critical medicines and components.

The alliance mirrors a wider shift in the contract development and manufacturing market, where companies are forming closer partnerships to present more unified offerings to biotech clients. For smaller developers with limited internal manufacturing expertise, integrated services can offer clearer accountability and fewer coordination challenges.

The effectiveness of the arrangement will depend on how closely the two organisations align quality systems and operational standards. As peptide drugs move into larger-scale production, reliable domestic GMP infrastructure is likely to become an increasingly important factor in supplier selection.